Key facts
- It has raised $30K; the latest was Seed Round in Feb 2025.
- Notable investors include LX Health, Launch Pad (Australia), VentureCrowd.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for MedaData
- ·The full record, as it builds
Funding rounds
No funding rounds for MedaData are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MedaData
Developer of an AI-enabled prescribing decision support platform designed to improve patient outcomes. The company's platform is developed to analyze specific, de-identified patient information in conjunction with medical guidelines and resources, enabling clients, particularly clinicians, to improve patient outcomes through evidence-based and accurate prescribing.
- Sector
- Healthcare
- HQ
- Sydney, Australia
- Founded
- 2021
- Employees
- 2
- Website
- medadata.com.au/
- Ownership
- Privately Held (backing)
MedaData doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MedaData shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MedaData in its N-PORT filings yet. We sweep new filings monthly.